This phase I trial is trying to determine how safe and tolerable a new intravenous drug (RO7296682) is in treating patients with advanced solid cancers (excluding some types of blood cancer).
This trial is treating patients with advanced solid cancers (excluding some blood cancers).
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
An Open-label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, PK (Pharmacokinetics)/PD (Pharmacodynamics) of RO7296682, a T-regulatory Cell Depleting Antibody in Participants With Advanced and/or Metastatic Solid Tumors
This trial is divided into a dose-escalation (Part A) and dose-expansion (Part B) stage. Eligible patients enrolled in Part A will receive ascending doses of RO7296682 intravenously every three weeks until a maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) is defined. Part B of the study will commence once the MTD/RP2D has been defined. Eligible patients enrolled in this part of the study will receive a fixed dose of RO7296682 at the MTD/RP2D established.
Recruiting Hospitals Read More